Medicenna in the spotlight (part IV)
Evaluating latest safety & biomarker data
Following up on our ongoing coverage of Medicenna (MDNA), this spotlight post will cover the company’s latest release of safety & biomarker data for the first two dose cohorts, which came out today. Early signs are promising.
MDNA’s monotherapy dose escalation will include 6 doses. The first dose was 0.003mg/kg. The second dose, which had data today, has…